Purpose <p>The correlation among the risk of gestational diabetes mellitus (GDM) and <i>CDKN2A/2B</i> rs10811661 polymorphism remains controversial, as previous studies have reported inconsistent findings. The potential relationship among the <i>CDKN2A/2B</i> rs10811661 polymorphism and GDM risk was examined by a meta-analysis.</p> Methods <p>In order to find relevant studies for our study, we performed an extensive search across several databases, including Embase, Pubmed, Web of science, Scopus, and China National Knowledge Infrastructure. Afterward, the link among the <i>CDKN2A/2B</i> rs10811661 polymorphism and the risk of GDM was then assessed using either random-effects models or fixed-effects to compute 95 percent confidence intervals (CIs) and pooled odds ratios (ORs).</p> Results <p>This meta-analysis comprised a total of 10 studies, and the results showed that the <i>CDKN2A/2B</i> rs10811661 polymorphism was linked to a decreased risk of GDM across all examined models. The pooled analysis demonstrated a substantial link, with the corresponding 95% CIs and the following ORs: Allele contrast: 0.68 (0.57–0.81), Homozygote 0.47,(0.32–0.69), Heterozygote 0.78, (0.68–0.88), Dominant model 0.69, (0.62–0.78), Recessive model 0.54(0.38–0.77). However, Trial Sequential Analysis (TSA) indicated that the Z-curve did not cross monitoring boundaries and the required information size (RIS) was not reached, suggesting that the evidence may be preliminary and should be interpreted with caution.</p> Conclusion <p>According to the current meta-analysis, the <i>CDKN2A/2B</i> rs10811661 variant may serve as a potential genetic biomarker for GDM, but additional large-scale studies are needed to confirm these findings.</p> Trial registration <p>The study was registered on PROSPERO (<a href="https://www.crd.york.ac.uk/prospero/">https://www.crd.york.ac.uk/prospero/</a>), registration number: CRD42023484296.</p>